keyword
MENU ▼
Read by QxMD icon Read
search

Dulaglutide

keyword
https://www.readbyqxmd.com/read/27921428/-promising-molecules-for-treatment-of-hyperglycemia-in-patients-with-type-2-diabetes
#1
Milan Kvapil
New antidiabetic drugs are being developed today that expand the range of pharmacological intervention, in particular for patients with type 2 diabetes (imeglimin, semaglutide, dulaglutide, FGF 21 analogue). At the same time innovations take place that "better" the well-proven molecules, they offer new application forms we have no experience of diabetology (osmotic pump for exenatide, faster acting insulin aspart). New properties are brought by just the change of concentration (insulin glargine in a concentration of 300 U/ml), unexpected positive results are also brought by new fixed-ratio combinations of antidiabetics (fixed-ratio combination of insulin degludec and liraglutide, fixed-ratio combination of insulin glargine and lixisenatide)...
2016: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/27917557/effect-of-12-week-dulaglutide-therapy-in-japanese-patients-with-biopsy-proven-non-alcoholic-fatty-liver-disease-and-type-2-diabetes-mellitus
#2
Yuya Seko, Yoshio Sumida, Saiyu Tanaka, Kojiroh Mori, Hiroyoshi Taketani, Hiroshi Ishiba, Tasuku Hara, Akira Okajima, Atsushi Umemura, Taichiro Nishikawa, Kanji Yamaguchi, Michihisa Moriguchi, Kazuyuki Kanemasa, Kohichiroh Yasui, Shunsuke Imai, Keiji Shimada, Yoshito Itoh
AIMS: No pharmacological therapies have been established for non-alcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus (T2DM). The aim of this retrospective study is to evaluate the efficacy and safety of dulaglutide, a novel glucagon-like peptidase-1 receptor agonist, in Japanese NAFLD patients with T2DM. METHODS: Fifteen biopsy-proven NAFLD patients with T2DM refractory to diet intervention who received once weekly dulaglutide 0.75 mg for 12 weeks were retrospectively enrolled after exclusion of two patients by 12 weeks...
November 2, 2016: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/27860132/occurrence-of-nausea-vomiting-and-diarrhoea-reported-as-adverse-events-in-clinical-trials-studying-glucagon-like-peptide-1-receptor-agonists-a-systematic-analysis-of-published-clinical-trials
#3
Karolin Bettge, Melanie Kahle, Mirna S Abd El Aziz, Juris J Meier, Michael A Nauck
AIM: GLP-1 receptor agonists (RAs) may cause nausea, vomiting or diarrhoea. The purpose was to assess the risk of adverse events (AEs) with GLP-1 RAs and their relation to dose, background medication and duration of action. MATERIAL AND METHODS: The PubMed database was searched and 32 clinical trials with GLP-1 RAs (phase 3) were selected. We performed a systematic analysis and compared the proportion of patients reporting nausea, vomiting or diarrhoea, for different doses and glucose-lowering background medications, and relative to a reference compound within the subclasses of short- (exenatide b...
November 9, 2016: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/27853058/pancreatic-safety-in-japanese-patients-with-type-2-diabetes-treated-with-once-weekly-dulaglutide-0-75-mg-up-to-52-weeks-in-phase-3-clinical-trials
#4
Masanori Emoto, Tomonori Oura, Akiko Matsui, Hirotaka Kazama, Noriyuki Iwamoto
The effects of incretin therapies on pancreatic safety are currently being evaluated. In 3 phase 3 clinical studies of once weekly dulaglutide 0.75 mg (dulaglutide) in Japanese patients with type 2 diabetes (T2D), symptoms suggestive of acute pancreatitis as well as pancreatic enzymes were assessed and the risk of acute pancreatitis was evaluated. Patients who met any of the predefined criteria (clinical signs/symptoms of acute pancreatitis, confirmed amylase or lipase level ≥3 times the upper limit of normal [ULN], abdominal imaging of the pancreas) were adjudicated for acute pancreatitis by a blinded external committee...
November 15, 2016: Endocrine Journal
https://www.readbyqxmd.com/read/27766728/the-effects-of-once-weekly-dulaglutide-on-kidney-function-in-patients-with-type-2-diabetes-in-phase-2-and-3-clinical-trials
#5
Katherine R Tuttle, T Dwight McKinney, Jaime A Davidson, Greg Anglin, Kristine D Harper, Fady T Botros
Dulaglutide (DU) is a once-weekly glucagon-like peptide-1 receptor agonist approved for treatment of type 2 diabetes. Integrated data from 9 phase 2 and 3 trials in type 2 diabetes (N = 6005) were used to evaluate effects of DU on estimated glomerular filtration rate (eGFR, mL/min/1.73m(2) [Chronic Kidney Disease Epidemiology Collaboration]), urine albumin-to-creatinine ratio (UACR, mg/g), and kidney adverse events. No significant differences in eGFR were observed during treatment for DU versus placebo (PL), active comparators (AC), or insulin glargine (IG) (mean±SD; DU: 87...
October 21, 2016: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/27766579/a-plethora-of-glp-1-agonists-decisions-about-what-to-use-and-when
#6
Susan L Samson, Alan J Garber
Incretin-based therapies are important addition to our armamentarium for the treatment of type 2 diabetes (T2DM). There are six Glucagon-like peptide-1 receptor agonists (GLP-1RAs) which have received regulatory approval for clinical use. The short-acting GLP-1RAs include exenatide twice daily, liraglutide once daily, and lixisenatide once daily. The approved long-acting GLP-1RAs are administered weekly and are exenatide, albiglutide, and dulaglutide. Although all of these therapies lower hemoglobin A1C (HbA1C), there also are unique features of GLP-1RAs that have been made manifest from clinical trial data with regard to weight-loss efficacy, fasting and post-prandial glucose control, cardiovascular safety and protection, and gastrointestinal and injection adverse effects...
December 2016: Current Diabetes Reports
https://www.readbyqxmd.com/read/27717130/glucagon-like-peptide-1-receptor-agonists-compared-with-basal-insulins-for-the-treatment-of-type-2-diabetes-mellitus-a-systematic-review-and-meta-analysis
#7
Sonal Singh, Eugene E Wright, Anita Ym Kwan, Juliette C Thompson, Iqra A Syed, Ellen E Korol, Nathalie A Waser, Maria B Yu, Rattan Juneja
AIMS: Since 2005, several glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been approved to treat people with type 2 diabetes. These agents are considered for use at the same point in the treatment paradigm as basal insulins. A comprehensive comparison of these drug classes, therefore, can help inform treatment decisions. This systematic review and meta-analysis assessed the clinical efficacy and safety of GLP-1 RAs compared with basal insulins. MATERIALS AND METHODS: MEDLINE, EMBASE, CENTRAL and PubMed databases were searched...
October 7, 2016: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/27673601/experience-from-development-of-once-weekly-glucagon-like-peptide-1-receptor-agonist-glp-1-ra-dulaglutide-for-treatment-of-type-2-diabetes-mellitus
#8
Z Milicevic
No abstract text is available yet for this article.
October 6, 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/27600499/the-efficacy-and-safety-of-liraglutide-added-to-metformin-in-patients-with-diabetes-a-meta-analysis-of-randomized-controlled-trials
#9
Jianqiu Gu, Xin Meng, Yan Guo, Lei Wang, Hongzhi Zheng, Yixuan Liu, Bingshu Wu, Difei Wang
Liraglutide, a glucagon-like peptide (GLP-1) receptor agonist, has showed favorable effects in the glycaemic control and weight reduction in patients with type 2 diabetes mellitus (T2DM). The meta-analysis was to compare the efficacy and safety of liraglutide added to metformin with other treatments in patients with T2DM. A systematic literature search on PubMed, Embase, Web of Science and the Cochrane library databases were performed. Eligible studies were randomized controlled trials (RCTs) of patients with T2DM who received the combination treatment of liraglutide and metformin...
September 7, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27540883/efficacy-and-safety-of-dulaglutide-in-hispanic-latino-patients-with-type-2-diabetes-in-the-award-clinical-program
#10
Jaime A Davidson, Federico Perez Manghi, Maria Yu, Bruno Linetzky, Laura Fernández Landó
OBJECTIVE: The aim of this post hoc analysis was to assess the efficacy and safety of once-weekly dulaglutide in Hispanic/Latino patients with type 2 diabetes (T2D) in phase 3 AWARD trials 1 to 6. METHODS: Hispanic/Latino data at Week 26 were pooled across studies for each dulaglutide dose to analyze the change from baseline in glycosylated hemoglobin (HbA1c), percent to HbA1c goal, and adverse events (AEs). Change from baseline in HbA1c, change from baseline in weight and hypoglycemia were analyzed by Hispanic/Latino and non-Hispanic/Latino subgroups for each study...
December 2016: Endocrine Practice
https://www.readbyqxmd.com/read/27531946/glucagon-like-peptide-1-glp-1-receptor-agonists-in-cardiac-disorders
#11
Jamie Wroge, Nancy Toedter Williams
OBJECTIVE: To evaluate the literature about the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the treatment of cardiac disorders, specifically myocardial infarction (MI) and heart failure (HF). DATA SOURCES: Searches were conducted in MEDLINE (1946-May 2016) and Excerpta Medica (1980-May 2016) using EMBASE with the search terms glucagon-like peptide 1, exenatide, albiglutide, liraglutide, dulaglutide, myocardial infarction, heart failure, and cardiovascular The references of relevant articles were reviewed to identify additional citations...
August 16, 2016: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/27524889/evaluating-preferences-for-profiles-of-glucagon-like-peptide-1-receptor-agonists-among-injection-naive-type-2-diabetes-patients-in-japan
#12
Heather L Gelhorn, Elizabeth D Bacci, Jiat Ling Poon, Kristina S Boye, Shuichi Suzuki, Steven M Babineaux
OBJECTIVE: The objective of this study was to use a discrete choice experiment (DCE) to estimate patients' preferences for the treatment features, safety, and efficacy of two specific glucagon-like peptide-1 receptor agonists, dulaglutide and liraglutide, among patients with type 2 diabetes mellitus (T2DM) in Japan. METHODS: In Japan, patients with self-reported T2DM and naive to treatment with self-injectable medications were administered a DCE through an in-person interview...
2016: Patient Preference and Adherence
https://www.readbyqxmd.com/read/27488824/dulaglutide-in-the-treatment-of-adult-type-2-diabetes-a-perspective-for-primary-care-providers
#13
John Anderson, Vivian Thieu, Kristina S Boye, Ryan T Hietpas, Luis-Emilio Garcia-Perez
Approximately 90% of T2D patients in the US are diagnosed and treated in the primary care setting, and the majority of the burden of disease management falls to primary care providers. Here, we discuss the clinical data for once weekly dulaglutide, e.g. the results of seven completed Phase 3 trials, patient preference studies, patient reported outcomes (PRO), and clinical data surrounding the dulaglutide administration device. Dulaglutide 1.5 mg once weekly demonstrated superiority to placebo, metformin, sitagliptin, exenatide BID, and insulin glargine (in 2 trials), and non-inferiority to liraglutide in reduction of HbA1c from baseline, with an acceptable safety profile...
August 4, 2016: Postgraduate Medicine
https://www.readbyqxmd.com/read/27488246/the-combination-of-dulaglutide-and-biguanide-reduced-bodyweight-in-japanese-patients-with-type-2-diabetes
#14
Nobuya Inagaki, Eiichi Araki, Tomonori Oura, Akiko Matsui, Masakazu Takeuchi, Yukio Tanizawa
The efficacy and safety of once-weekly dulaglutide 0.75 mg (dulaglutide) in Japanese patients with type 2 diabetes (T2D) were evaluated according to subgroups defined by concomitant oral hypoglycaemic agents. This exploratory analysis included data from a randomized, open-label, phase III study that compared dulaglutide with insulin glargine (glargine) (n = 361). The three subgroups were dulaglutide or glargine in combination with sulphonylurea (SU) alone, biguanide (BG) alone or SU and BG combined. There were no clinically relevant differences in glycated haemoglobin (HbA1c) changes among the three subgroups in the dulaglutide group; in the glargine group, a numerically greater reduction was observed in combination with BG alone compared to the other two groups (SU alone and SU + BG)...
December 2016: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/27485823/adjunctive-role-of-glucagon-like-peptide-1-receptor-agonists-in-the-management-of-type-1-diabetes-mellitus
#15
REVIEW
Kira B Harris, Cassie L Boland
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly used in combination with insulin to manage type 2 diabetes mellitus, and four agents are currently approved for this indication: exenatide, liraglutide, dulaglutide, and albiglutide. The distinctive properties of GLP-1 RAs-potential hemoglobin A1c (A1C) reduction, weight loss, potential to reduce insulin doses, and lower hypoglycemia risk-have made these agents potential treatment options for patients with type 1 diabetes mellitus (T1DM) as well...
September 2016: Pharmacotherapy
https://www.readbyqxmd.com/read/27456750/efficacy-and-safety-of-once-weekly-glucagon-like-peptide-1-receptor-agonists-compared-with-exenatide-and-liraglutide-in-type-2-diabetes-a-systemic-review-of-randomised-controlled-trials
#16
REVIEW
X Xue, Z Ren, A Zhang, Q Yang, W Zhang, F Liu
BACKGROUND: Once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown promising results in the treatment of type 2 diabetes. Herein, we compared the efficacy and safety of once-weekly GLP-1RAs with exenatide and liraglutide separately. METHODS: We systematically surveyed the pertinent literature using various databases. The randomised controlled trials that compared once-weekly GLP-1RAs with exenatide and liraglutide in type 2 diabetes were included...
August 2016: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/27382338/the-treatment-of-type-2-diabetes-in-the-presence-of-renal-impairment-what-we-should-know-about-newer-therapies
#17
REVIEW
Melanie Davies, Sudesna Chatterjee, Kamlesh Khunti
Worldwide, an estimated 200 million people have chronic kidney disease (CKD), the most common causes of which include hypertension, arteriosclerosis, and diabetes. Importantly, ~40% of patients with diabetes develop CKD, yet evidence from major multicenter randomized controlled trials shows that intensive blood glucose control through pharmacological intervention can reduce the incidence and progression of CKD. Standard therapies for the treatment of type 2 diabetes include metformin, sulfonylureas, meglitinides, thiazolidinediones, and insulin...
2016: Clinical Pharmacology: Advances and Applications
https://www.readbyqxmd.com/read/27340935/glp1-ra-add-on-therapy-in-patients-with-type-2-diabetes-currently-on-a-bolus-containing-insulin-regimen
#18
REVIEW
Marie L Davies, David Q Pham, Scott R Drab
Adding glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to basal insulin regimens has become a guideline-recommended treatment option for uncontrolled type 2 diabetes. However, limited data exist to support the use of GLP-1 RAs with insulin regimens, including bolus insulin in patients with type 2 diabetes. The primary objectives of this review were to identify if the combination of a GLP-1 RA and an insulin regimen containing bolus insulin resulted in improvements in HbA1c , weight loss, reduction in insulin doses, and to evaluate the side effect profile of this combination in terms of nausea and hypoglycemia risk...
August 2016: Pharmacotherapy
https://www.readbyqxmd.com/read/27330280/mode-of-administration-of-dulaglutide-implications-for-treatment-adherence
#19
REVIEW
Ambika Amblee
BACKGROUND: Medication complexity/burden can be associated with nonadherence in patients with type 2 diabetes mellitus (T2DM). Patients' satisfaction with their treatment is an important consideration for physicians. Strategies like using longer acting efficacious agents with less frequent dosing may help adherence. OBJECTIVE: To explore the mode of administration of dulaglutide and its implications for treatment adherence in T2DM. METHODS: PubMed search using the term "Dulaglutide" through October 31, 2015 was conducted...
2016: Patient Preference and Adherence
https://www.readbyqxmd.com/read/27318907/-impact-of-glucagon-like-peptide-1-receptor-agonists-on-nasopharyngitis-and-upper-respiratory-tract-infection-among-patients-with-type-2-diabetes-a-network-meta-analysis
#20
Z X Li, S S Wu, Z R Yang, S Y Zhan, F Sun
OBJECTIVE: To systematically review the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on two common respiratory system adverse events (RSAE: nasopharyngitis and upper respiratory tract infection) among type 2 diabetes (T2DM). METHODS: Medline, Embase, Clinical trials and Cochrane library were searched from inception through May 2015 to identify randomized clinical trials(RCTs) assessed safety of GLP-1RAs versus placebo or other anti-diabetic drugs in T2DM...
June 18, 2016: Beijing da Xue Xue Bao. Yi Xue Ban, Journal of Peking University. Health Sciences
keyword
keyword
27533
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"